Status:
COMPLETED
Urinary Schistosomiasis Infection
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Diseases of the Urinary System
Schistosomiasis Haematobia
Eligibility:
All Genders
Up to 99 years
Brief Summary
The purpose of this study is to determine what causes some people to become sick, and others not, when they are infected with the parasite Schistosoma haematobium, also known as Bilharzia. This is an ...
Detailed Description
The goal of this project is to focus both field and laboratory research on specific epidemiological, genetic and immunological features that underline the greatest susceptibility to S. haematobium inf...
Eligibility Criteria
Inclusion
- Kenyan residents, newborn to adult, either male or female.
- Residence in areas of Kwale District endemic for Schistosoma haematobium
Exclusion
- Pregnancy (this is a partial exclusion). Pregnant women will participate in the parasitological screening phase of the study. However, because of pregnancy-related effects on the urinary system, their ultrasound examinations will be excluded from the analysis of hydronephrosis. Further, because of potential toxicity of praziquantel (Category B) and its alternative, metrifonate (an anticholinesterase), post-protocol anti-parasitic therapy will be delayed until the mother delivers and has stopped breastfeeding her infant.
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
November 1 2004
Estimated Enrollment :
4400 Patients enrolled
Trial Details
Trial ID
NCT00138450
End Date
November 1 2004
Last Update
January 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KEMRI Centre for Geographic Medicine Research
Kilifi, Kenya